Abstract
We investigated the association between potential regulatory variants in key genes in carcinogenesis and clinical outcome of patients with advanced stage non-small cell lung cancer (NSCLC) who underwent first-line paclitaxel-cisplatin chemotherapy. In the discovery set, 509 variants were genotyped. In the validation set, the association 96 variants and chemotherapy response or overall survival in 379 patients with stage III or IV NSCLC was analyzed. Among studied variants, the rs10414193A>G was significantly associated with worse response to chemotherapy. (odds ratio = 0.63, 95% CI = 0.47-0.85, p = 0.002, under additive genetic model). The rs10414193A>G was also associated with significantly worse overall survival (hazard ratio = 1.25, 95% CI = 1.08-1.45, p = 0.004, under additive genetic model). In vitro functional study, luciferase activity was significantly higher in A549 cells transfected with pGL3-LKB1 pro_G compared with pGL3-LKB1 pro and pGL3-LKB1 pro_A (p=0.017 and p=0.0009, respectively). In conclusion, this study showed that rs10414193A>G may be a predictor of clinical outcomes after first-line paclitaxel-cisplatin chemotherapy in patients with advanced stage NSCLC.
Footnotes
Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, OA3301.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2018